ProfileGDS5678 / 1429786_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 82% 82% 83% 84% 83% 81% 82% 82% 83% 84% 84% 86% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6414780
GSM967853U87-EV human glioblastoma xenograft - Control 26.0459882
GSM967854U87-EV human glioblastoma xenograft - Control 35.9963282
GSM967855U87-EV human glioblastoma xenograft - Control 46.2979983
GSM967856U87-EV human glioblastoma xenograft - Control 56.308384
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8201983
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6205681
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9096782
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9528982
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1704483
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1480384
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3365684
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.442386
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1180583